Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Sullivan

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Blood|October 19, 2017
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasmsMargaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Blood|May 23, 2018
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitorsSilvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Cell Reports|October 7, 2020
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow MicroenvironmentBac Viet Le, Paulina Podszywalow-Bartnicka, Silvia Maifrede, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
Blood|December 29, 2022
DNA polymerase θ protects leukemia cells from metabolically induced DNA damageUmeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, et al.
Cancer Research|July 3, 2021
<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP InhibitorsSilvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Blood|October 19, 2017
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasmsMargaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Blood|May 23, 2018
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitorsSilvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Cell Reports|October 7, 2020
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow MicroenvironmentBac Viet Le, Paulina Podszywalow-Bartnicka, Silvia Maifrede, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
Blood|December 29, 2022
DNA polymerase θ protects leukemia cells from metabolically induced DNA damageUmeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, et al.
Cancer Research|July 3, 2021
<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP InhibitorsSilvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, et al.
Pageof 6